Indefinite Delivery Contract 75D30120D07111
Award Date
1/7/20
Last Date to Order
2/28/21
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325411 - Medicinal and Botanical Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention (CDC) awarded a single award Indefinite Delivery Contract to Glaxosmithkline, LLC, a pharmaceutical company, to procure pediatric influenza vaccines for the 2022-2023 season. The contract has a potential value of $168,590,000 and a period of performance from the date of award through February 28, 2023. The original solicitation sought between 100 doses and 50 million doses of pediatric influenza vaccine to be delivered to CDC distribution centers in...
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides adult flu vaccines for the 2023-2024 period. Glaxosmithkline, LLC was awarded a multiple award contract with a potential value of $13.9 million to deliver flu vaccines through February 2028 under associated task orders or price lists. The solicitation aimed to procure adult flu vaccines to support the Centers for Disease Control and Prevention's...
The Indefinite Delivery Contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh provides for pediatric flu vaccines for the 2023-2024 period. The multiple award contract has a potential value of $220.5 million and was awarded to Seqirus USA Inc. on December 31, 2022. The contract aims to procure pediatric flu vaccines through February 28, 2024 to support the Centers for Disease Control and Prevention's efforts in preventing the spread...
The federal contract IDV award to Glaxosmithkline, LLC is for the supply of pediatric influenza vaccines to the Centers for Disease Control and Prevention (CDC) for distribution to immunization programs under the Section 317(j) Public Health Service Act and Vaccines for Children program. The single-award contract has a ceiling value of $161,025,000 and a period of performance from December 31, 2020 to February 28, 2022. The contract was issued in response to a CDC solicitation for a minimum...
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to the pharmaceutical company Glaxosmithkline, LLC to provide pediatric influenza vaccines for the 2024-2025 timeframe. The contract has a ceiling value of $182,592,000 and a period of performance through February 28, 2025. Glaxosmithkline, a foreign-owned for-profit organization, has extensive experience as a prime contractor providing a range of pharmaceutical products and services to...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) Office of Acquisition Services, a civilian federal agency, to GlaxoSmithKline Holdings (Americas) Inc. The contract has a ceiling value of $20,661,104.25 and a period of performance from March 15, 2010 to February 28, 2011. The contract appears to be for the procurement of flu vaccine products and related services as part of the CDC's Vaccine for Children (VFC) program. While the exact scope...
This indefinite delivery contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh to provide pediatric flu vaccines for 2023-2024. Astrazeneca Pharmaceuticals LP is the prime contractor for this multiple-award contract with a potential value of $58.53M. The contract aims to procure pediatric flu vaccines through a series of task orders against an established price list. As the lead federal agency for public health emergency...
The Centers for Disease Control and Prevention awarded an indefinite delivery contract to Glaxosmithkline, LLC for adult influenza vaccines. The contract has a potential value of $13.41 million to supply a minimum of 100 doses and maximum of 20 million doses of inactivated influenza vaccine for individuals aged 19 years and older through February 28, 2023. Vaccines must be licensed by the FDA and manufactured in compliance with cGMP regulations. Delivery locations include CDC distribution...
The Centers for Disease Control and Prevention awarded a single-award indefinite delivery contract to Glaxosmithkline, LLC to procure adult influenza vaccines. The contract has a potential value of $13 million and a period of performance from December 2020 through February 2022. The original solicitation sought proposals for the purchase of influenza vaccines for individuals aged 19 years and older to support immunization programs under Section 317(j) of the Public Health Service Act. Offerors...
This indefinite delivery contract, awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, provides for the purchase of 20 different pediatric vaccines for the CDC's Vaccines for Children program. The contract has a $986,824,450 ceiling value and a period of performance from April 1, 2020 through March 31, 2021. Glaxosmithkline, as the prime contractor, will supply vaccines such as DTaP, Hep A and B, Hib, HPV, MMR, pneumococcal, rotavirus, and varicella in...